Biomed Valley Discoveriesbvdis A Clinical Stage Biotechnology Company Based In Kansas Citymissourifounded In 2007Bvd Focuses On Developing Innovative Medicines To Meet Significant Unmet Patient Needsespecially In Oncology And Other Serious Conditionsthe Company Benefits From A Unique Funding Model That Allows It To Pursue High Risk Projectsemphasizing Long Term Patient Impact Over Short Term Financial Returns Bvd Specializes In Early Stage Development And Employs A Data Driven Scientific Approach To Advance Promising Research Programsone Of Its Key Products Is Ulixertinibbvd 523 A Selective Inhibitor Targeting The Mapk Pathway For Patients With Specific Cancersthe Company Is Also Engaged In Other Oncology Programsincluding Tem8 And Cnv Ntbvd Collaborates With Physician Researchers And Centers Of Excellenceleveraging A Global Network To Enhance Its Research And Development Efforts While Maintaining A Lean Operational Structure
